skip to Main Content

Nusinersen patient Q&As

  • 19 May 2020

Patient organisations have asked for NICE and NHS to answer a few very important questions with regards to MAA and access to Nusinersen. We are now able to share their answers in the attached documents. We will continue to push for expanded access for this treatment to make sure that everybody gets a chance.

Read More

AveXis gets EC approval for Zolgensma

  • 19 May 2020

AveXis, a Novartis company, announced today that the European Commission (EC) have granted conditional approval for Zolgensma for the treatment of patients with 5q SMA, activating a ‘Day One’ access programme.

Read More
Back To Top